Gliclazide
Gliclazide
CAS: 21187-98-4
Molecular Formula: C15H21N3O3S
Gliclazide - Names and Identifiers
Gliclazide - Physico-chemical Properties
| Molecular Formula | C15H21N3O3S |
| Molar Mass | 323.41 |
| Density | 1.2205 (rough estimate) |
| Melting Point | 163-169 °C (lit.) |
| Solubility | methylene chloride: soluble |
| Appearance | White powder |
| Color | white |
| Merck | 14,4439 |
| pKa | 6.07±0.10(Predicted) |
| Storage Condition | 2-8°C |
| Refractive Index | 1.6740 (estimate) |
| MDL | MFCD00409893 |
| Physical and Chemical Properties | Melting point 163-169°C |
| Use | Hypoglycemic agents for the treatment of non-insulin-dependent diabetes mellitus |
Gliclazide - Risk and Safety
| Risk Codes | R21 - Harmful in contact with skin R36/38 - Irritating to eyes and skin. R46 - May cause heritable genetic damage R62 - Possible risk of impaired fertility R63 - Possible risk of harm to the unborn child |
| Safety Description | S25 - Avoid contact with eyes. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37 - Wear suitable protective clothing and gloves. S53 - Avoid exposure - obtain special instructions before use. S24/25 - Avoid contact with skin and eyes. |
| UN IDs | 3077 |
| WGK Germany | 2 |
| RTECS | YT4500000 |
| HS Code | 29350090 |
| Toxicity | LD50 orally in mice: >3 g/kg (Duhault) |
Gliclazide - Standard
Authoritative Data Verified Data
This product is l-(3-azabicyclo [3.3.0] Octyl)-3-p-toluenesulfonylurea. Calculated as the dried product, the content of C15H21N3O3S shall not be less than 98.5%.
Last Update：2024-01-02 23:10:35
Gliclazide - Trait
Authoritative Data Verified Data
- This product is white crystal or crystalline powder; Odorless.
- This product is dissolved in chloroform, slightly soluble in methanol, slightly soluble in ethanol, insoluble in water.
melting point
The melting point of this product (General 0612) is 162~166°C.
Last Update：2022-01-01 15:35:59
Gliclazide - Differential diagnosis
Authoritative Data Verified Data
- take this product, dissolve and dilute with ethanol to make a solution containing about 10ug per lml, and measure by UV-Vis spectrophotometry (General 0401), there is a maximum absorption at a wavelength of 228nm.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 629).
Last Update：2022-01-01 15:35:59
Gliclazide - Exam
Authoritative Data Verified Data
Related substances
take about 50mg of this product, accurately weigh it, put it in a 50ml measuring flask, add about 20ml of acetonitrile to dissolve it, dilute it with water to the scale, shake it well, and use it as a test solution; take 5ml accurately, put it in a 40% measuring flask, dilute it to the scale with acetonitrile solution, shake it well, and use it as the control solution (1); Take 2ml of the control solution (1) accurately, place it in a 50ml measuring flask, dilute to the scale with 40% acetonitrile solution, shake well, and use it as control solution (2 ) ; Take 1-(3-azabicyclo [3.3.0] Octyl)-3-o-toluenesulfonylurea (impurity I) control about 10mg, put in a 100ml measuring flask, add about 40ml of acetonitrile to dissolve, dilute with water to the scale, shake, as a control solution (1); 1ml of the control solution (1) was accurately measured, placed in a 40% measuring flask, diluted to a scale with acetonitrile solution, and shaken to obtain the control solution (2). 2ml of the control solution (1) and 3ml of the control solution (1) were placed in the same 20ml measuring flask, diluted to the scale with 40% acetonitrile solution, and shaken to obtain the system applicable solution. Test according to high performance liquid chromatography (General 0512). The mobile phase was water-acetonitrile-triethylamine-trifluoroacetic acid (60:40:0.1:0.1). The detection wavelength was set at 235nm. The system applicable solution 20u1 is injected into the liquid chromatograph, and the chromatogram is recorded. The number of theoretical plates is not less than 3000 based on the Gliclazide peak, and the separation degree between the Gliclazide peak and impurity I peak should be greater than 1.8. The sample solution, the control solution (2) and the reference solution (2) were respectively injected with 20ul, and the chromatogram was recorded to 2 times of the retention time of the main component peak. If there are chromatographic peaks in the chromatogram of the test solution that are consistent with the retention time of the main peak of the reference solution (2), the peak area shall be calculated according to the external standard method, and shall not exceed 0.1%; other single impurity peak area shall not be greater than 0.5 times (0.1%) of the main peak area of the control solution (2); The sum of other impurity peak areas shall not be greater than the main peak area of the control solution (2) (0.2%). All solutions should be freshly prepared.
loss on drying
take this product, dry to constant weight at 105°C, weight loss shall not exceed 1.0% (General rule 0831).
ignition residue
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
Heavy metals
The residue left under the item of taking the ignition residue shall not contain more than 10 parts per million of heavy metal when examined by law (General Principles 0821, Law II).
Last Update：2022-01-01 15:36:00
Gliclazide - Content determination
Authoritative Data Verified Data
take this product about 0.2g, precision weighing, add glacial acetic acid 50ml dissolved, according to the potential titration method (General 0701), with perchloric acid titration solution (0.1 mol/L) titration, and the results of the titration were corrected with a blank test. Each 1 ml of perchloric acid titration solution (0.1 mol /L) corresponds to 32.34mg of C15H21N303S.
Last Update：2022-01-01 15:36:01
Gliclazide - Category
Authoritative Data Verified Data
hypoglycemic drugs.
Last Update：2022-01-01 15:36:01
Gliclazide - Storage
Authoritative Data Verified Data
light shielding, sealed storage.
Last Update：2022-01-01 15:36:01
Gliclazide - Gliclazide tablets (II)
Authoritative Data Verified Data
This product contains Gliclazide (C15H21N303S) should be the label amount of 93.0% ~ 107.0%.
trait
This product is white tablet.
identification
- take an appropriate amount of fine powder of this product (about 0.4g of Gliclazide), extract with chloroform shaking for 2 times, 10ml each time, filter, and evaporate the filtrate on a water bath, the residue was dissolved in ethanol and diluted to give a solution containing about 10ug per 1 ml, which had an absorption maximum at a wavelength of 0401 nm as determined by UV-visible spectrophotometry (general).
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- take an appropriate amount of fine powder of this product (equivalent to 0402 mg of Gliclazide), add of dichloromethane, grind and dissolve, filter, evaporate the filtrate, dry the residue under reduced pressure, and determine it according to law (general rule). The infrared absorption spectrum of this product should be consistent with the spectrum of the control (Spectrum set 629 figure).
examination
- Related substances take an appropriate amount of fine powder of this product (about equivalent to Gliclazide lOOmg), put it in a 100ml measuring flask, add about 40ml of acetonitrile to dissolve Gliclazide, dilute it to the scale with water, shake it well, filter it, take the filtrate as the test solution; Take 2ml of precision measurement, put it in a 40% measuring flask, dilute it with acetonitrile solution to the scale, shake it, take 5ml of precision measurement and put it in a 50ml measuring flask, as a control solution, it was diluted to the mark with 40% acetonitrile solution and shaken. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (0.2% ) , the sum of each impurity peak area shall not be greater than 2 times (0.4%) of the main peak area of the control solution. All solutions should be freshly prepared.
- dissolution the dissolution of this product was determined according to the dissolution and release determination method (General rule 0931 method 1), with phosphate buffer (pH 8.6) 150 ml as the dissolution medium, and the rotation speed was rpm, operate according to the law, at 60 minutes and 180 minutes, take 8ml of the solution, filter, immediately add 8ml of phosphate buffer (pH 8.6) to the dissolution Cup, and take the filtrate as the test solution; another 20mg of Gliclazide reference substance was added into 250ml measuring flask, and the appropriate amount of dissolution medium was added. The solution was dissolved by shaking in a warm water bath, shake well as a control solution. 5ml of the test solution and 5ml of the reference solution were respectively placed in a 25ml measuring flask, diluted to the scale with dissolution medium, and shaken, the absorbance was measured at a wavelength of 0401 NM according to ultraviolet-visible spectrophotometry (general rule), and the elution amount of each tablet at the above two times was calculated. The amount of dissolution at 60 minutes and 180 minutes shall be respectively not more than 50% of the label amount and not less than 75% of the label amount, and the results shall be determined according to the sustained-release preparation and shall comply with the regulations.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
- measured by high performance liquid chromatography (General 0512).
- chromatographic conditions and system suitability test using octanosilane bonded silica as filler; Using water-acetonitrile-triethylamine-trifluoroacetic acid (60:40:0.1:0.1) as mobile phase; the detection wavelength was 235nm. The number of theoretical plates shall not be less than 3000 calculated by Gliclazide peak, and the separation degree between Gliclazide peak and adjacent impurity peak shall meet the requirements.
- determination of 20 tablets of this product, precision weighing, fine grinding, precision weighing fine powder appropriate amount (equivalent to Gliclazide 20mg ), put 100ml flask, add 40% acetonitrile solution about 60ml, dissolve Gliclazide by ultrasound, dilute to the scale with 40% acetonitrile solution, shake well, filter, as a test solution, take 20u1 accurately and inject human liquid chromatograph, record chromatogram; another 10 mg of gliclazide was added into a 50ml measuring flask, and 20ml of acetonitrile was added to dissolve the solution. The solution was diluted with water to scale, shaken, measured and calculated by the same method. All solutions should be freshly prepared.
category
Same as Gliclazide.
specification
80mg
storage
light shielding, sealed storage.
Last Update：2022-01-01 15:36:02
Gliclazide - Reference Information
| EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
| Hypoglycemic drug | Gliclazide (G1iclazide), the chemical name is 1-(hexahydrocyclopentane [c] pyrrole -2(1H)-yl)-3-(4-methylphenyl) sulfonylurea is the second-generation sulfonylurea oral hypoglycemic drug, which also has the dual effects of lowering blood sugar and improving coagulation function, it can not only improve the metabolism of diabetic patients, but also improve or delay the occurrence of diabetic vascular complications. Developed by a French SERVIER company, it was first listed in France in 1972. The trade names are Damikang, Methylpyridoxene, Methylsulfonyl Bicyclic Urea, Leicepam, Methylsulfonyl Urea, Glicnassa, mainly used for In adulthood, the onset of mild and middle type II diabetes, which is ineffective in diet and exercise control, and has no tendency to ketosis, can also improve fundus diseases and metabolic and vascular dysfunction in diabetic patients. It can be combined with biguanide oral hypoglycemic drugs, combined with insulin to treat insulin-dependent diabetes, which can reduce the amount of insulin. It began to supply the Chinese market in the 1980 s and has now been registered and sold in more than 130 countries around the world. |
| pharmacological action | 1. hypoglycemic effect: this product is the second generation of oral sulfonylurea hypoglycemic drugs, and its effect is more than 10 times stronger than tolbutamide. The mechanism of action is to stimulate islet β cells to release insulin and reduce hyperglycemia. This may be due to the fact that sulfonylurea drugs bind to receptors on the surface of β cells and increase their activation and increase the sensitivity of peripheral target tissues to insulin. 2. Reduce platelet aggregation and adhesion, prevent fibrin deposition on microvessels. 3. Reduce cholesterol accumulation and plasma concentrations of arterial triglycerides and fatty acids. The three functions, in addition to the treatment of diabetic metabolic disorders, can also prevent and treat diabetic complications-the occurrence and development of vascular, retinal, and renal dysfunction. |
| mechanism of action | gliclazide has a strong effect. its mechanism is to selectively act on islet β cells to promote insulin secretion and improve insulin release after eating glucose, thus inhibiting glycogen production and output. It has a hypoglycemic effect on adult diabetic patients, and can reduce cholesterol accumulation, reduce the plasma concentration of aortic glycerin triphosphate and fatty acids, so gliclazide can not only treat diabetic metabolic disorders, but also prevent diabetic microangiopathy, Improve retinopathy and renal function. |
| pharmacokinetics | oral absorption is faster; plasma concentration peaks in 2~6 hours. The plasma protein binding rate is 94.2%, T1/2 is about 12 hours. This product is mainly metabolized in the liver, and the metabolites have no hypoglycemic effect. The 98% is excreted by the kidney within 48 hours, and the content of primary drugs in the urine is less than 5%. |
| synthesis method | using cyclopentane o-diformic anhydride as raw material, ammoniated to obtain cyclopentane o-diformimide, catalyzed by LiAlH4, KBH4/ZnCl2 or platinum black to obtain azabicyclo, and then reduced by nitrosation and zinc powder to obtain N-amino -3-azabicyclo [3,3,O] octane hydrochloride, finally, it is condensed with p-toluene sulfonylurea to obtain gliclazide. Fig. 2 shows the synthesis route of gliclazide |
| use | for adults with type 2 diabetes, diabetes with obesity or with vascular disease. hypoglycemic drugs, used for the treatment of non-insulin-dependent diabetes hypoglycemic drugs, non-insulin-dependent diabetes. |
| adverse reactions | occasionally mild nausea, vomiting, epigastric pain, constipation, diarrhea, erythema, urticaria, thrombocytopenia, neutropenia, anemia, etc., most of which disappeared after drug withdrawal. |
| taboo | 1. those who are allergic to this product, sulfonylureas and sulfonamides are prohibited. It is forbidden for patients with type 2.1 diabetes. 3. Patients with pre-diabetic coma and diabetic ketoacidosis are prohibited. 4. Patients with severe liver and kidney insufficiency are prohibited. 5. Patients with leukopenia are disabled. 6. Patients with stress such as coma, severe burns, infection, trauma and major surgery are prohibited. 7. Pregnant and lactating women are prohibited. |
| precautions | patients with type 1.2 diabetes should switch to insulin therapy when they have stress such as infection, trauma, surgery, ketoacidosis and non-ketotic hyperosmolar diabetic coma. 2. When the dosage of this product is too large, eating too little or strenuous exercise, attention should be paid to prevent hypoglycemia. 3. The patient's blood sugar and urine sugar must be checked regularly, and ophthalmic examination must be carried out. 4. When combined with anticoagulant drugs, regular coagulation examination should be done. (2015-12-02) |
| drug interaction | when combined with non-steroidal anti-inflammatory drugs (especially salicylate), sulfonamides, dicoumarin anticoagulants, monoamine oxidase inhibitors, β-receptor blockers, tetracycline, chloramphenicol, bicyclohexyperidine, chlorobebutyl ester, ethanol and other drugs, the dosage should be reduced to avoid hypoglycemia. |
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: Gliclazide Visit Supplier Webpage Request for quotationCAS: 21187-98-4
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Gliclazide Request for quotation
CAS: 21187-98-4
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 21187-98-4
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Multiple SpecificationsSpot supply
Product Name: Gliclazide Visit Supplier Webpage Request for quotationCAS: 21187-98-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Gliclazide Visit Supplier Webpage Request for quotationCAS: 21187-98-4
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Gliclazide Request for quotation
CAS: 21187-98-4
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 21187-98-4
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Multiple SpecificationsSpot supply
Product Name: Gliclazide Visit Supplier Webpage Request for quotationCAS: 21187-98-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History